Pas de connexion internet — affichage de la version enregistrée de la page.

Arrowhead Pharmac…

USUSD
← Vers le Screener
US:ARWRLSE:0HI3

Arrowhead Pharmaceuticals Inc (LSE:0HI3) — Biotechnology: Pharmaceutical Preparations. Nombre de places boursières sur lesquelles les actions de la société sont cotées : 2. Sur cette page : cours et graphique, dividendes, principaux actionnaires et historique du nombre d'actions.

À propos de l'entreprise

Site Web
arrowheadpharma.com
Secteur
Health Care · Biotechnology: Pharmaceutical Preparations
Siège Social
Pasadena, United States
PDG
Christopher R. Anzalone
Employés
711
Fondée
2004
Actions en Circulation
141.25 M au 2026-07-30
Flottant
122.45 M
Capitalisation Boursière
9.22 Md USD
Initiés
3.66%
Investisseurs Institutionnels
85.47%
Secteur d'Activité (SIC)
Pharmaceutical Preparations
ISIN
US04280A1007
LEI
549300O3CSB8T7OZ3D66
FCF
−75.1 M USD
Dette
181 M USD
Résultats et FCF — pour les 12 mois à 30.06.2026 (dernier rapport de l'entreprise).
Description

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clinical trials. The company also develops ARO-INHBE, to reduce the hepatic expression of the INHBE gene and its secreted gene product, Activin E in Phase 1/2a clinical trials; ARO-ALK7 to silence adipocyte expression of the ACVR1C gene in Phase 1/2a clinical trials; ARO-RAGE to reduce production of the receptor for advanced glycation end products in Phase 1/2a clinical trials; and ARO-MAPT, an investigational RNAi-based therapy. In addition, it is developing ARO-C3 to reduce production of C3 in Phase 1/2a clinical trials; and ARO-CFB to reduce hepatic expression of CFB in a Phase 1/2a clinical trials. The company has collaboration and license Agreements with Glaxosmithkline Intellectual Property (No. 3) Limited; Takeda Pharmaceutical Company Limited; Amgen Inc.; and Sarepta Therapeutics, Inc. Arrowhead Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Pasadena, California.

publicité

Bourses et Tickers

BourseTickerDevisePrixType
US USA StocksARWR principaleUSD58.13 -4.28%actions ordinaires
LSE London Stock Exchange0HI3 IOBUSD65.82 +0.00%actions ordinaires

Cours sur 3 Mois

jour de hausse jour de baisseSurvolez / touchez un jour — cours d'ouverture, de clôture, plus haut et plus bas

Principaux Actionnaires

DétenteurParticipationActionsDate du Rapport
Blackrock Inc.10.53%14.83 M2026-06-30
Avoro Capital Advisors L…8.06%11.36 M2026-06-30
FMR, LLC5.71%8.04 M2026-06-30
Vanguard Portfolio Manag…4.51%6.35 M2026-06-30
Vanguard Capital Managem…4.34%6.11 M2026-06-30
State Street Corporation4.04%5.69 M2026-06-30
iShares Trust-iShares Co…3.5%4.93 M2026-08-31
VANGUARD INDEX FUNDS-Van…3.01%4.25 M2026-06-30
NORGES BANK2.77%3.9 M2026-06-30
Invesco Ltd.2.76%3.88 M2026-06-30
ANZALONE CHRISTOPHER RIC…≈2.69%3.79 M2026-01-02
Geode Capital Management…2.51%3.53 M2026-06-30
Fred Alger Management, L…2.34%3.3 M2026-06-30
VANGUARD INDEX FUNDS-Van…2.18%3.07 M2026-06-30
Fidelity Mt. Vernon Stre…1.81%2.55 M2026-07-31
Invesco Exchange-Traded…1.27%1.79 M2026-08-31
VANGUARD INDEX FUNDS-Van…1.26%1.77 M2026-06-30
VANGUARD INDEX FUNDS-Van…1.15%1.61 M2026-06-30
SPDR SERIES TRUST-State…1.05%1.48 M2026-08-31
SPDR S&P MIDCAP 400 ETF…0.73%1.03 M2026-08-31
iShares Trust-iShares Bi…0.69%968 7382026-07-31
O'BRIEN PATRICK C (Chief…≈0.39%547 4082026-01-06
MYSZKOWSKI KENNETH ALLEN…≈0.32%455 4332025-01-07
HAMILTON JAMES C (Office…≈0.16%226 9582026-04-23
APEL DANIEL JOSEPH (Chie…≈0.12%162 9052026-04-22
GIVEN DOUGLAS BRUCE (Dir…≈0.09%124 1672024-12-17
PERRY MICHAEL S (Directo…≈0.08%111 4592026-08-18
FERRARI MAURO (Director)≈0.05%69 0532025-12-26
WADDILL WILLIAM D (Direc…≈0.04%56 5632025-12-19
LU HONGBO B (Director)≈0.04%52 0122026-05-12